BioVersys' Alpibectir Combination Shows Promise in Overcoming TB Drug Resistance

Event summary

  • BioVersys published pre-clinical data in Nature Communications demonstrating Alpibectir's unique mechanism in potentiating ethionamide (Eto) to overcome drug-resistant tuberculosis (TB).
  • AlpE (Alpibectir + Eto) showed potent activity against diverse M. tuberculosis strains, including resistant ones, in both in vitro and in vivo studies.
  • AlpE is currently in a Phase 2b pulmonary TB trial expected to finalize recruitment by end of 2027 and a Phase 2 trial for TB meningitis initiated recently.
  • Alpibectir has received orphan-drug designation from both the FDA and EMA, providing market exclusivity incentives.

The big picture

BioVersys' publication in Nature Communications underscores the growing need for innovative solutions to combat drug-resistant TB, a global health crisis with rising mortality rates. The strategic collaboration with GSK and academic institutions highlights the importance of public-private partnerships in advancing anti-infective research. With the TB market valued at billions and the urgency to address MDR-TB strains, AlpE's potential to overcome drug resistance could position BioVersys as a key player in the infectious disease space.

What we're watching

Clinical Trial Progress
The pace at which the Phase 2b pulmonary TB trial and the Phase 2 TB meningitis trial progress will determine the next stages of clinical development for AlpE.
Regulatory Pathway
Whether the orphan-drug designation from the FDA and EMA will expedite the regulatory approval process for AlpE.
Market Exclusivity
How the 7-year US market exclusivity and 10-year EU market exclusivity will impact BioVersys' commercial strategy for AlpE.